{"retracted":false,"update":{"timestamp":1353542400000,"doi":"10.1007/bf03259762","type":"correction"},"doi":"10.2165/00042310-199302090-00002","journal":"Drugs & Therapy Perspectives","publisher":"Springer Nature","title":"Erratum to Gliclazide: good clinical profile but relatively high acquisition costs"}
